Finanzen von Agomab Therapeutics NV (AGMB)AGMBAgomab Therapeutics NV

In the context of the broader market, AGMB competes directly with industry leaders such as CRMD and VSTM. With a market capitalization of $651.06M, it holds a significant position in the sector. When comparing efficiency, AGMB's gross margin of N/A stands against CRMD's 75.66% and VSTM's 89.92%. Such benchmarking helps identify whether Agomab Therapeutics NV is trading at a premium or discount relative to its financial performance.

Agomab has a negative EPS of -0.71 for Q3 2024 and a forward P/E ratio of 0, indicating it is not yet profitable but is investing in future growth through clinical trials.